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Abstract
Temporal lobe necrosis (TLN) is the most debilitating late-stage complication after radiation therapy in patients
with nasopharyngeal cancer (NPC). The bilateral temporal lobes are inevitably encompassed in the radiation field
and are thus prone to radiation induced necrosis. The wide use of 3D conformal and intensity-modulated radiation
therapy (IMRT) in the treatment of NPC has led to a dwindling incidence of TLN. Yet, it still holds great significance
due to its incapacitating feature and the difficulties faced clinically and radiologically in distinguishing it from a
malignancy. In this review, we highlight the evolution of different imaging modalities and therapeutic options. FDG
PET, SPECT and Magnetic Spectroscopy are among the latest imaging tools that have been considered. In terms of
treatment, Bevacizumab remains the latest promising breakthrough due to its ability to reverse the pathogenesis
unlike conventional treatment options including large doses of steroids, anticoagulants, vitamins, hyperbaric
oxygen and surgery.
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Introduction
Nasopharyngeal cancer (NPC) is highly prevalent in
Southern China, particularly in Guangdong province and
in the northern parts of Africa and Inuits of Alaska [1].
Till date radiotherapy remains the mainstay treatment of
NPC [2]. A definitive radiation dose between 66 Gy and
70 Gy needs to be given to the gross tumor volume
(GTV), and 54-60 Gy to the clinical target volume (CTV).
More than 70% of patients with NPC present with stage
III or IV disease, among whom extensive skull base inva-
sion or even cavernous sinus involvement commonly
occur [3]. Treatment with radiation therapy under these
circumstances exposes parts of the temporal lobes to
doses over 60 Gy. This greatly increases the risks of tem-
poral lobe necrosis (TLN) which is one of the most debili-
tating late stage complications after radiotherapy in NPC.
The majority of radiation induced TLN patients with
NPC that have been reported in the literature were
treated with conventional 2D radiotherapy rather than
3D or IMRT. An incidence of TLN of 4.6% in 10 years
(conventional fractionation) [4] to 35% in 3.5 years
(accelerated fractionation to 71.2 Gy) [5] has been
observed. Classical histological findings of TLN include
various degrees of coagulative necrosis of brain parench-
yma associated with fibrinoid changes of blood vessels
while demyelination without blood vessel changes may
be observed in less severely affected areas [6]. Other his-
tological features include oligodendrocyte dropping out,
axonal swelling, reactive gliosis, and disruption of the
blood brain barrier [7,8].
Clinical presentations of TLN are variable, and four
main types have been well described by Lee et al [9]. 39%
of their patients presented with vague symptoms includ-
ing occasional dizziness and impairment of memory and
personality changes, 31% had features of temporal lobe
epilepsy, 16% had no signs or symptoms and were inci-
dentally diagnosed during investigation for other neuro-
logic and endocrine dysfunction after radiation therapy,
while 14% of the patients suffered from symptoms of
raised intracranial pressure and nonspecific symptoms
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convulsion as a result of mass effect.
Differential diagnosis of TLN includes intracranial
extension of NPC, second primary intracranial malig-
nancies, hematogenous cerebral metastasis and brain
abscess [10]. It is easier to exclude brain abscess on the
basis of symptoms and laboratory investigations sugges-
tive of infection. On the other hand, hematogenous cer-
ebral metastasis from NPC are extremely rare [11].
Both tumor and radiation necrosis can cause vasogenic
edema, disrupt the blood-brain barrier and cause cavita-
tions. Clinically, both conditions can present with features
of raised intracranial pressure and show contrast enhance-
ment on MRI. Thus, a diagnostic dilemma sometimes
arises when trying to differentiate TLN from neoplasm
(intracranial extension of NPC or a second primary intra-
cranial malignancy). We recently reported a case report
about such an ambiguous situation leading to delay in the
institution of the appropriate treatment [12]. Many times
a working diagnosis can still be reached without resorting
to biopsy by carefully correlating the history, reviewing the
treatment plan, correlating the high dose volume with
TLN and the findings on conventional imaging. Yet, the
lack of specificity of conventional imaging has prompted
the search for a more reliable diagnostic tool.
Diagnostic Modalities
Conventional imaging
Among the different anatomical imaging available, MRI
appears to have higher sensitivity than CT in diagnosing
TLN. However, CT scan is best suited to rule out skull
base erosions [13]. Warranting brief attention are two
characteristic features of TLN on CT: the early finger like
hypodense area representative of reactive white matter
edema and the late cyst like changes corroborating with
liquefactive necrosis and surrounding gliosis [9]. The fin-
ger and the cyst signs on CT are seen as irregular and
rounded lesions on MRI respectively [13]. The features in
favor of TLN include two characteristic enhancement pat-
terns - the “Swiss cheese” and “soap bubble” [14,15]. Also,
TLN lesions are usually restricted within the portals of
radiation though they may extend well beyond.
Advanced Imaging Tools
Advanced imaging techniques are mainly functional ima-
ging techniques which assess physiological parameters
and can provide additional information about the lesions.
Perfusion and diffusion weighted MRI
Perfusion MRI allows a non-invasive evaluation of cere-
bral blood flow (CBF) and relative regional cerebral
blood volume (rrCBV). Neovascularised tumors manifest
a higher CBF due to the high blood volume and blood
flow to the tumor bed. On the other hand, temporal lobe
radiation necrosis exhibits low vascularity and hence a
lower CBF. Dynamic susceptibility contrast MRI is a
form of perfusion MRI, during which dynamic MRI
images is rapidly taken over time, after the patient is
given a bolus injection of a paramagnetic contrast med-
ium. During the perfusion phase, the contrast enters the
intravascular compartment and is recorded as a drop of
signal intensity. However, as the contrast medium moves
rapidly into the extracellular compartment at the end of
t h ep e r f u s i o np h a s e ,ar i s ei ns i g n a li n t e n s i t yi sn o t e d .
The transient drop in the signal intensity is prominent in
tumors, as a result of their increased angiogenesis, that
results in the magnetic susceptibility effects of contrast
accumulation in the intravascular compartment. Several
parameters including cerebral blood flow, time to
enhancement, and cerebral blood volume can be evalu-
ated from this technique. Tsui et al used dynamic sus-
ceptibility contrast MRI to study the rrCBV of nine NPC
after radiotherapy who presented with clinical features of
temporal lobe necrosis [16]. In this study, all but one
patient had low signal on T1 and high signal on T2
images with heterogeneous enhancement and demon-
strated marked hypoperfusion on the rrCBV maps. A
recent study suggests that perfusion MRI might be super-
ior to FDG PET and C-MET [17]. It also offers the
advantage that it can be performed at the same time as
conventional MRI. The potential pitfalls of perfusion
MRI include susceptibility artifacts, relative but not abso-
lute quantification of CBV and inaccurate determination
of CBV in cases of severe disruption or absence of blood
brain barrier [18].
Perfusion MRI can be used in conjunction with diffusion
weighted MRI. It is speculated that a failure of the Na
+-K
+
pump leads to an influx of water from the extracellular
compartment to intracellular space which forms the basis
of the net decrease of diffusion coefficient [19]. In the
brain parenchyma the diffusion of water is impeded by
various structures including membranes and myelin
sheath so that presence of tumor further impedes water
movement due to the added cell membrane mass. Appar-
ent diffusion coefficient (ADC) maps are obtained which
may be compared with rCBV maps of perfusion MRI for
‘mismatch’. Radiation necrosis generally displays marked
high diffusion on ADC while the relative CBV map reveals
marked hypoperfusion due to damage of the endothelial
cells and ischemia leading to a “diffusion and perfusion
mismatch" [20]. Tsui et al established the diagnosis of
temporal lobe necrosis of 16 NPC patients who developed
clinical symptoms or ambiguous radiation induced tem-
poral lobe abnormalities on conventional MRI by diffusion
and perfusion MRI [21]. He noted a larger abnormality on
the rCBV map compared to the ADC map which he con-
cluded was due to presence of injured but potentially
salvageable brain tissue. However, paradoxical findings
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presumably with radiation induced brain necrosis. Le
Bihan et al reported a low ADC value in radiation necrosis
patients [22]. This may be due to the fact that radiation
induced necrosis is usually composed of a mixture of dif-
ferent components. Further prospective studies are
required to clearly establish the clinical usefulness of the
mismatch pattern.
Magnetic resonance spectroscopy
Whereas MRI provides morphological information, MR
spectroscopy allows direct, noninvasive quantification of
various metabolites and the study of their distribution in
different tissues. Metabolites, such as choline (Cho), N
acetyl aspartate (NAA), creatinine (Cr) and lipid-lactate
(Lip-Lac) spectrum, are quantified. Lip-Lac peaks reflect
anaerobic metabolism. Increased choline levels represent
enhanced cellular membrane phospholipid synthesis
accompanying tumor cell proliferation [23,24]. Areas
believed to be radionecrotic will usually show lowered
Cho while high Cho is obtained in areas with dense
viable tumor cells. NAA functions as a neuronal integrity
marker and is decreased in both tumor and radionecrosis
due to neuronal destruction. A decrease in NAA levels
on single voxel MR spectroscopy was reported in all 18
NPC patients in a study with imaging evidence of radia-
tion induced TLN, and this decrease was evident even
before a change in Cho or Cr levels [25]. Creatinine indi-
cates cellular energy metabolism and is fairly stable
under most conditions. It is therefore used as the
denominator in metabolic ratio calculations such as Cho/
Cr and NAA/Cr ratios, even though some reports have
questioned the stability of Cr in tumors, hypoxia and
other confounding conditions [26]. MR spectroscopy has
been used to differentiate between tumor and radiation
changes, and even guide the management of patients as
reported by Smith et al [27]. Patients with a Cho/NAA
ratio of less than 1.1 were assigned for imaging follow-
up; those with a higher ratio of more than 2.3 underwent
immediate treatment in line with tumor while patients
with Cho/NAA ratios between these values would
undergo biopsy. As a drawback, MRS lacks the ability to
precisely identify the boundaries of a tumor and radiation
necrosis when they co-exist at the same location. There is
no consensus yet on the calculated threshold which can
best distinguish radiation necrosis from a tumor. Unlike
PET, MRS does not have the disadvantage of ionizing
radiation. However, MRS and PET still play a comple-
mentary role in classifying indeterminate brain lesions
into non-neoplastic and neoplastic.
Positron emission tomography
The use of functional FDG PET appeared to be promis-
ing on a theoretical basis by measuring the uptake of 2-
[¹⁸F] DeoxyGlucose (FDG). Tumors are thought to be
usually hypermetabolic and thus show an increased
uptake of FDG, while radiation necrosis is hypometa-
bolic. Di Chiro et al reported a 100% sensitivity and spe-
cificity with PET in the differentiation of tumor from
radiation necrosis in one of the largest samples of
patients where all cases were pathologically con-
firmed [28]. Studies carried out after 1990s, unfortu-
nately have defied the above conclusion [29-33]. PET
has been shown to have a high sensitivity of about 80%
but low specificity of 40%. Causes of false negative PET
scanning of a tumor include recent radiation therapy,
low histological grade and small tumor volume, while
false positive PET in radiation-induced brain injury
could be due to activated repair mechanisms or inflam-
matory activity [34]. It is therefore suggested that
GdTPA MRI should be used in conjunction with FDG
PET when making a diagnosis of a suspected case of
radiation necrosis [34]. PET also has the disadvantage of
being expensive, not widely available and exposing the
patient to radiation.
In order to improve its specificity, different radiophar-
maceuticals have been tried like the
13N-NH3 [35] and
11C Methionine (MET) in place of FDG. 11 C-methionine
is the commonest amino acid tracers that has been stu-
died. Methionine, is one of the essential amino acids
which is required for protein synthesis and its derivatives
S-adenosyl methionine acts as a methyl donor as well as a
precursor for the synthesis of polyamine. Due to an
increase in these activities, in cases of malignancy, an
increase uptake of this tracer is observed in such patients
[36]. Since the uptake of amino acid is low in normal
brain tissue as compared to tumor, a better contrast can
be obtained between the two, with MET-PET scanning as
opposed to FDG-PET [37]. MET-PET allows for the iden-
tification of low grade brain tumors including gliomas,
even when no uptake is visible on FDG PET [37]. The
high cost and limited availability of PET scans spurred the
consideration of alternative imaging tools such as Thal-
lium-201 single photon emission computed tomography
(
201Tl SPECT).
Single photon emission computed tomography
201Tl SPECT is efficacious and a less costly method com-
pared to PET. Thallium is a potassium analog that has
been used for many years in myocardial perfusion ima-
ging. It is presumed that the uptake of Thallium by
tumor cells relies on a combination of mechanisms
including blood brain barrier disruption, blood flow and
Na
+/K
+ ATPase pump activity [38,39]. It can differentiate
between tumor and radiation necrosis and even estimate
the grade of a tumor [38]. It reflects viable tumor burden
more accurately than CT, MR, or other radionuclide stu-
dies [40-43]. Radiation induced necrotic tissue does not
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mechanism and Na
+/K
+ ATPase enzyme while tumor
cells have increased levels of this enzyme, therefore con-
centrate Thallium-201. Moreover, Thallium is taken up
in increasing amounts with increasing histological grade
of the tumor. The slightly lower spatial resolution com-
pared to PET is one of the main setbacks of SPECT.
Other Clues For Diagnosis
The levels of circulating plasma EBV DNA levels may con-
tribute in differentiating between tumor and TLN. Mea-
surement of free plasma EBV DNA has been found to be a
highly specific and sensitive marker of nasopharyngeal car-
cinoma [44]. EBV DNA is released into blood after lysis of
NPC cells and hence reflects the tumor load. Hou et al
found that pre-treatment plasma EBV DNA concentra-
tions significantly correlated with tumor volume, T stage
and TNM stage. They also believe that pre-treatment EBV
DNA concentrations mainly reflect tumor load whereas
post treatment EBV DNA concentrations are an important
predictive factor for distant metastases [45]. Leung et al
reported that pre-treatment plasma EBV DNA concentra-
tions could predict distant metastasis in early stage
N P C[ 4 6 ] .L oe ta la l s os h o w e dt h a tc i r c u l a t i n gp l a s m a
EBV DNA copies increase significantly in NPC patients
with tumor recurrence [44], and the EBV DNA levels can
significantly increase sometimes up to 6 months earlier
than clinical diagnosis. A considerably high pretreatment
level of EBV DNA and a subsequent rise during follow
up may therefore indicate tumor recurrence and may
aid in differentiating tumor from TLN in ambiguous
circumstances.
Despite the multiple attempts to distinguish tumor from
TLN by radiological methods, biopsy still remains the
most reliable way to reach an unequivocal diagnosis since
no radiological technique has yet the capacity to reliably
differentiate between these two entities.
Prevention
Prevention remains the cornerstone of a successful thera-
peutic algorithm for TLN. It is practically impossible to
completely shield the temporal lobes during radiotherapy
for NPC patients with skull base invasion or cavernous
sinus involvement. Kam et al showed that IMRT signifi-
cantly limits the maximal dose to the temporal lobes to 46
Gy as compared to 66.5 Gy in 2D radiotherapy in NPC
patients with T4N2M0 disease [47]. Additionally, replan-
ning for patients with NPC before the 25th fraction during
IMRT further helps to ensure adequate dose to the target
volumes and safe doses to critical normal structures,
which may decrease incidence of TLN [48,49].
Among the multiple etiologies of TLN, the fraction size
is of utmost significance [4]. Lee et al analyzed the inci-
dence rate of temporal lobe necrosis in 1008 patients
treated radically with different fractionation schedules for
T1 NPC [4]. 621 patients, who received a lower total
dose of 50.4 Gy in 4.2 Gy per fraction, had a significantly
higher 10 year actuarial incidence rate of TLN compared
to the 320 patients who received a higher total dose of
60 Gy but in 2.5 Gy per fraction: 18% versus 4.6% respec-
tively. Apart from fractional dose, in a later study, they
identified the overall treatment time and the twice daily
schedule as additional etiologic factors of TLN [50]. The
5 year actuarial incidence of TLN in this study ranged
from 0% in patients who had received 66 Gy in 2 Gy per
fraction once daily as compared to 14% in patients who
received two fractions per day during part of the treat-
ment (71.2 Gy in 40 fractions in 35 days). Furthermore,
in a retrospective analysis of 849 NPC patients treated
with radiation therapy alone, Yeh et al observed that
patients receiving external beam radiation dose more
than 72 Gy experienced a higher incidence of temporal
lobe necrosis [51]. Moreover, the use of boost has
improved local control, especially of locally advanced
NPC but at the cost of an increase in toxicity. Hara et al
reported a 12% incidence of TLN among their 82 NPC
patients at a median follow up of 3.4 years, who were
treated with external beam RT to 66 Gy followed by ster-
otactic radiotherapy (SRT) boost of 7-15 Gy in a single
fraction [52]. Likewise, during a 5 year follow-up, Lee
et al observed a rate of 8.3% of TLN among 33 patients
of theirs, who received 5 Gy SRT boost in 2 fractions
after conformal RT to a total dose of 70 Gy [53].
By stringently limiting doses to the temporal lobes,
using conventional fraction size, adoption of IMRT and
replanning during IMRT, occurrence of TLN can be pre-
vented in most patients. Control of comorbid factors like
hypertension, diabetes, lipidemia, obesity and smoking,
which are known contributory factors in the development
of TLN, may also reduce the incidence and severity of the
sequelae.
Treatment
Treatment of TLN is still a challenging issue. Treatment
modalities for cerebral radio-necrosis are also suitable for
radiation-induced TLN. Observation may be the only
treatment needed in some selective patients with TLN
including those that are asymptomatic, have a long latency
period of TLN development, have received only one
course of radiotherapy and have favorable MRI
findings [54].
Steroids
Steroids have been used to provide prompt symptomatic
relief. Radionecrosis is usually associated with various
degrees of white matter edema in the early phase, which
acts as a space occupying lesion and hinders the blood
supply to the temporal lobe. Steroids help decrease
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decreases cerebral edema but also minimizes the risk of
subsequent development of vascular and inflammatory
changes [55]. Unfortunately, they are seen to be beneficial
only in early phase of extensive liquefactive necrosis[9].
Tapered doses of dexamethasone achieved a durable
response in 25 out of 72 NPC patients studied by Lee et al
who had radiation induced TLN [9]. The reported doses
of dexamethasone used range from 4-16 mg/day for 4-6
weeks and were gradually tapered off [9]. Prolonged use of
steroids is associated with various side effects like diabetes,
myopathy and weight gain [56]. However, steroids also
have immunosuppressive effects on the already immuno-
compromised cancer patients and put them at high risk of
developing fatal sepsis and death [9]. Furthermore, since
steroids do not reverse the pathogenesis, many patients
experience the symptoms again after they are tapered off
the medication [7]. In a recent study, pulsed steroid treat-
ment, which has better tolerance and may minimize long
term steroid induced side effects, has been compared to
oral steroids in the treatment of TLN in NPC patients.
The clinical and radiological outcomes were found to be
better with the use of pulsed steroids. 20% patients experi-
enced radiological improvement as opposed to 3.2% of
patients receiving conventional oral steroids (p < 0.0001)
which could be due to the comparatively lower pulsed-
steroid dose used as compared to oral steroids. These
results should be interpreted with caution as baseline
characteristics and the follow-up protocols of the treat-
ment groups were different [54].
Anticoagulants, anti-platelets and vitamins
Glantz et al were the first to report the use of heparin fol-
lowed by warfarin for 3-6 months in an attempt to treat
radiation necrosis by arrest and reversal of endothelial
injury which is the predisposing lesion entailing to radia-
tion necrosis [57]. This therapeutic option was met with
little success since the symptoms reemerged after their
discontinuation. Anti-platelet treatment with pentoxyfyl-
lin, aspirin, and ticlopidine have also been used to pre-
vent thrombosis of the blood vessels but the potential
risk of bleeding from these agents should be consid-
ered [7]. At present, there are still no large clinical trials
to support their routine use in the treatment of radiation
induced necrosis. High doses of vitamins such as alpha
tocopherol has shown the ability to improve the neuro-
cognitive function of radiation induced temporal lobe
necrosis in NPC patients in a phase II trial when it was
administered for a period of 1 year [58].
Hyperbaric oxygen
Hyperbaric oxygen (HBO) has also been tried in radiation
necrosis patients [59]. It raises the Pa02 of tissues and
initiates cellular and vascular repair. Oxygen is delivered
at 2.0 to 2.4 atm in 20-30 sessions for 90-120 min per
session. Chuba et al treated 10 patients of radiation
necrosis with hyperbaric oxygen among whom 6 showed
improvements with 3 having documented radiographic
response [60]. However, many also received concomitant
steroid treatment. Serious complications of hyperbaric
oxygen are rare but may include oxygen toxicity and
closed cavity barometric pressure trauma. There have
been concerns about tumor regrowth with increased oxy-
genation, but this has not been supported by Feldme-
ier [61,62]. However, a recent study suggests that HBO
therapy may increase risk of cancer re-recurrence in
patients who had locoregional recurrence and success-
fully salvaged head and neck cancer [63]. Further studies
are required to confidently establish its efficacy and safety
and understand its implication in treatment of TLN.
Surgery
Surgery is usually reserved as the last resort in patients
with significant increase in intracranial pressure or in
those with progressive neurological deficits despite ster-
oids or other medical therapy [31]. It may also be indi-
cated in cases of TLN complicated by hemorrhage or
brain abscess formation [8,64]. Previously, conflicting out-
comes have been obtained with neurosurgery, with good
outcomes in some [65] while poor in others [9]. Recently,
Mou et al performed surgery for 14 patients with histolo-
gically confirmed TLN, who failed to show improvement
with steroids [66]. Good surgical outcome with significant
symptom improvement and low recurrence rate was
obtained. The results from the above study depict that sur-
gery may not only cause partial reversal of the radionecro-
tic process, but also halt the progression of radiation
necrosis. Similar results were reported in an another
recent study where 27 radiation induced TLN patients
with NPC had emergency life saving neurosurgery [54].
Generally, patients with good performance status, well-
controlled primary disease and good prognosis may be
expected to fare better with surgery. Until now surgery
has only been performed in a small sample size and many
questions concerning its use still warrant further
clarification.
Bevacizumab
Bevacizumab is the latest addition to the therapeutic
options for radiation induced TLN. Gonzalez et al
firstly reported a group of 8 patients with radiation-
induced brain necrosis treated with bevacizumab on
either a 5 mg/kg/2-week or a 7.5 mg/kg/3-week sche-
dule. In all 8 patients significant reductions in dexa-
methasone dose as well as abnormalities on MRI fluid-
attenuated inversion-recovery (FLAIR) corresponding
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alities corroborating with capillary permeability were
noted [67]. Similar observations were reported in other
studies [68]. These remarkable changes are thought to
be the result of normalization of the blood brain bar-
rier by bevacizumab [67]. Besides improvement in ima-
ging parameters, Wong et al reported significant
improvement of neurocognitive deficits [69]. It is pos-
tulated that fibrinoid necrosis of blood vessels and
hypoxia leads to VEGF release [70]. Additionally,
radiation-induced damage of astrocytes further causes
leakage of VEGF. This then acts on the capillary tar-
gets and causes neovascularization. The new vessels
are leaky and further perpetuate edema and blood
brain barrier disruption [70,71]. Bevacizumab, there-
fore seems to have both a diagnostic and therapeutic
role. A randomized double-blind placebo-controlled
trial of bevacizumab therapy for radiation necrosis of
central nervous system, involving 14 patients, was car-
ried out [72]. A dose of 7.5 mg/kg of bevacizumab was
administered 3 weekly in one group while the other
group received intravenous placebo [72]. Final results
depicted that all bevacizumab-treated patients, while
none of the placebo-treated patients showed improve-
ment in neurological symptoms or signs. However, one
of the limitations of this study remains its small sam-
ple size.
Preliminary results have shown that bevacizumab at a
dose of 7.5 mg/kg every 3 weeks, or 5 mg/kg every two
weeks for 12 weeks can stop the progression of radiation
necrosis, or even reverse its process in most patients with
limited follow-up [72]. A recent case report has shown
a more rapid and early onset of relief of symptoms accom-
panied with a long lasting response with bevacizumab
than steroids in the treatment of TLN in a NPC
patient [56]. However, most studies using bevacizumab to
treat brain necrosis involve small sample size, and their
longest follow-up is just 10 months. It is hence necessary
to prolong the follow-up to see whether the efficacy is dur-
able or not. For example, a recent case report from Japan
described two patients with radiation necrosis treated with
5 mg/kg of bevacizumab biweekly for 6 cycles [73]. There
was an improvement in neurocognitive function and peri-
focal edema. However, signs of radiation necrosis appeared
again several months after discontinuation of the drug.
Fortunately the patients still responded to a second course
of bevacizumab. This case report as well as previous stu-
dies emphasize on the need for further research to deter-
mine the optimal dose, the longest interval between doses
to achieve durable resolution of CNS radiation necrosis
and its long term safety through larger sample size studies.
More recently, the use of mouse nerve growth factor
for 2 months in a NPC patient with clinical and radiolo-
gical manifestations of radiation induced TLN showed
complete resolution of the MRI abnormalities and an
improved cognitive function in one case report [74].
However, no definite conclusions can be formulated
from this report since it involves only one patient whose
TLN was not confirmed by histology and the follow up
period is short. Hence further studies are required.
Conclusion and Perspectives
After a brief analysis of all t h ee v i d e n c ea v a i l a b l eu n t i l
now concerning the diagnosis and treatment of TLN,
we still do not have a definite algorithmic management
for this entity. However, a few conclusions can still be
drawn:
1. Prevention is always better than treatment in the
management of TLN. IMRT is definitely the radiothera-
peutic technique of choice for treatment of NPC at pre-
sent, considering its normal organ sparing ability
together with its capacity to achieve adequate tumorici-
dal dose. Furthermore, the mutifactorial etiologies of
TLN including dose fraction size should always be kept
in mind when treating NPC patients.
2. In cases where a definite diagnosis of TLN is difficult
to make according to conventional radiological modalities
like CT and MRI, a panoply of functional imaging techni-
ques including MRS, perfusion MRI, and PET might aid in
diagnosis. Furthermore, evaluation of EBV DNA plasma
level can provide a clue.
3. Until now conventional treatment including ster-
oids and anticoagulants fails to reverse the pathogenesis
of TLN and merely used for palliation. However,
recently bevacizumab has gained much interest in the
management of this entity since it holds the potential of
reversing the underlying pathogenesis. Since its use is
still in the initial phase, critical questions such as its
optimal dose and duration of administration still needs
further investigation.
4. Further elucidation of the pathogenesis of TLN at the
molecular level may open new frontiers in therapeutic
options.
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